Trial Profile
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Venetoclax (Primary)
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2021 Results assessing the safety of the combination of venetoclax plus BEAM followed by ASCT presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 29 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 29 Sep 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.